Newswire (Published: Tuesday, September 18, 2018, Received: Thursday, September 13, 2018, 4:38:35 PM CDT)

Word Count: 551

New Prostate Cancer Findings Reported from Netherlands Comprehensive Cancer Organisation (Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting out of Utrecht, Netherlands, by NewsRx editors, research stated, "To investigate men's values and preferences regarding prostate-specific antigen (PSA)-based screening for prostate cancer. Systematic review. We searched MEDLINE, EMBASE, PsycINFO and grey literature up to 2 September 2017."

Our news journalists obtained a quote from the research from Netherlands Comprehensive Cancer Organisation, "Primary studies of men's values and preferences regarding the benefits and harms of PSA screening. Two independent reviewers extracted data and assessed risk of bias with a modified version of a risk of bias tool for values and preferences studies, the International Patient Decision Aid Standards instrument V.3 and the Cochrane Collaboration risk of bias tool. We identified 4172 unique citations, of which 11 studies proved eligible. Five studies investigated PSA screening using a direct choice study design, whereas six used decisions aids displaying patient-important outcomes. The direct choice studies used different methodologies and varied considerably in the reporting of outcomes. Two studies suggested that men were willing to forego screening with a small benefit in prostate cancer mortality if it would decrease the likelihood of unnecessary treatment or biopsies. In contrast, one study reported that men were willing to accept a substantial overdiagnosis to reduce their risk of prostate cancer mortality. Among the six studies involving decision aids, willingness to undergo screening varied substantially from 37% when displaying a hypothetical reduction in mortality of 10 per 1000 men, to 44% when displaying a reduction in mortality of 7 per 1000. We found no studies that specifically investigated whether values and preferences differed among men with family history, of African descent or with lower socioeconomic levels. The variability of men's values and preferences reflect that the decision to screen is highly preference sensitive."

According to the news editors, the research concluded: "Our review highlights the need for shared decision making in men considering prostate cancer screening."

For more information on this research see: Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review. Bmj Open, 2018;8(9):e025470. (BMJ Publishing Group -; Bmj Open -

Our news journalists report that additional information may be obtained by contacting R.W.M. Vernooij, Dept. of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands. Additional authors for this research include L. Lytvyn, H. Pardo-Hernandez, L. Albarqouni, C. Canelo-Aybar, K. Campbell and T. Agoritsas (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Utrecht, Oncology, Netherlands, Kallikreins, Endopeptidases, Prostate Cancer, Serine Proteases, Peptide Hydrolases, Health and Medicine, Prostatic Neoplasms, Risk and Prevention, Enzymes and Coenzymes, Diagnostics and Screening, Prostate Specific Antigen.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC


BMJ Publishing Group Limited


Western Europe


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer